NCT00546182

Brief Summary

We hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2004

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

October 17, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 18, 2007

Completed
Last Updated

October 18, 2007

Status Verified

October 1, 2007

First QC Date

October 17, 2007

Last Update Submit

October 17, 2007

Conditions

Hypercholesterolemia

Keywords

Lipophilic statinsInsulin resistancehypercholesterolemic patients

Outcome Measures

Primary Outcomes (1)

  • simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients

Eligibility Criteria

Age25 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Study Population

overweight hypercholesterolemic patients

You may qualify if:

  • Low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0

You may not qualify if:

  • Patients with overt liver disease
  • Chronic renal failure
  • Hypothyroidism, myopathy
  • Uncontrolled diabetes
  • Severe hypertension, stroke
  • Acute coronary events
  • Coronary revascularization within the preceding 3 months, or
  • Alcohol abuse.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gil Medical Center, Gachon University

Incheon, 405760, South Korea

Location

Related Publications (1)

  • Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999 Mar;126(5):1205-13. doi: 10.1038/sj.bjp.0702397.

    PMID: 10205010RESULT

MeSH Terms

Conditions

HypercholesterolemiaInsulin Resistance

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesHyperinsulinismGlucose Metabolism Disorders

Study Officials

  • Kwang K Koh, MD,PhD

    Gachon University Gil Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 17, 2007

First Posted

October 18, 2007

Study Start

January 1, 2004

Last Updated

October 18, 2007

Record last verified: 2007-10

Locations

KR(1)